patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug · antibody

save

BEYFORTUS

updated 2mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Fusion glycoprotein F0

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

BEYFORTUS

trade names

Beyfortus

generic

NIRSEVIMAB-ALIP

MOA

12.1 Mechanism of Action BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] .

indication

1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. BEYFORTUS is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. ( 1 ) Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. ( 1 )

BEYFORTUS

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside